Core Viewpoint - Twist Bioscience (TWST) has experienced significant selling pressure, resulting in a 33.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 typically indicating that a stock is oversold [2] - TWST's current RSI reading is 23.07, suggesting that the heavy selling may be exhausting, indicating a potential for a price rebound [5] - RSI helps investors identify potential entry points for stocks that have fallen below their fair value due to excessive selling pressure [3] Group 2: Fundamental Analysis - There has been a consensus among sell-side analysts to raise earnings estimates for TWST, with a 4.3% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7] - TWST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating strong potential for a turnaround [8]

[Forward-Looking Statements](index=5&type=section&id=FORWARD-LOOKING%20STATEMENTS) This section outlines the company's forward-looking statements, subject to various risks and uncertainties - The report contains forward-looking statements regarding future growth, expansion, operations, and financial performance, which are subject to numerous risks and uncertainties[11](index=11&type=chunk) - Key risks include the ability to increase revenue and growth rate, accurately estimate capital needs, manage growth, enter new markets, develop new products, protect intellectual property, manage competition, and adapt to technological changes[11](index=11&type=chunk) - Readers are cautioned not to rely on these statements as predictions of future events, and the Company undertakes no obligation to update them, except as required by law[12](index=12&type=chunk)[13](index=13&type=chunk) [Part I. Financial Information](index=7&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis [Item 1. Financial Statements (unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements) This section presents Twist Bioscience Corporation's unaudited condensed consolidated financial statements and related notes [Condensed Consolidated Balance Sheets (unaudited)](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20(unaudited)) Condensed Consolidated Balance Sheets (Unaudited) - Key Figures | Metric (in thousands) | June 30, 2025 | September 30, 2024 | Change | | :-------------------- | :------------ | :----------------- | :----- | | Total assets | $643,605 | $614,323 | +$29,282 | | Total liabilities | $165,407 | $141,634 | +$23,773 | | Total stockholders' equity | $478,198 | $472,689 | +$5,509 | | Cash and cash equivalents | $201,373 | $226,316 | -$24,943 | | Investment in equity securities | $54,337 | $1,525 | +$52,812 | | Liability related to sale of future revenue | $15,000 | $— | +$15,000 | [Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited)](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)%20(unaudited)) Condensed Consolidated Statements of Operations (Unaudited) - Key Figures | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :-------------------- | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Revenues | $96,057 | $81,464 | $277,563 | $228,264 |\ | Loss from operations | $(30,120) | $(88,922) | $(106,325) | $(184,788) |\ | Gain on sale of business | $48,847 | $— | $48,847 | $— |\ | Net income (loss) | $20,390 | $(85,571) | $(50,532) | $(174,071) |\ | Basic EPS | $0.34 | $(1.47) | $(0.85) | $(3.01) |\ | Diluted EPS | $0.33 | $(1.47) | $(0.85) | $(3.01) | [Condensed Consolidated Statements of Stockholders' Equity (unaudited)](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity%20(unaudited)) Stockholders' Equity Changes (Three Months Ended June 30, 2025) | Metric (in thousands) | March 31, 2025 Balance | Stock-based Compensation | Net Income | June 30, 2025 Balance | | :-------------------- | :--------------------- | :----------------------- | :--------- | :-------------------- | | Additional paid-in capital | $1,753,600 | $16,076 | — | $1,771,502 |\ | Accumulated deficit | $(1,312,830) | — | $20,390 | $(1,292,440) |\ | Total stockholders' equity | $440,108 | $16,076 | $20,390 | $478,198 | Stockholders' Equity Changes (Nine Months Ended June 30, 2025) | Metric (in thousands) | Sept 30, 2024 Balance | Stock-based Compensation | Net Loss | June 30, 2025 Balance | | :-------------------- | :-------------------- | :----------------------- | :------- | :-------------------- |\ | Additional paid-in capital | $1,715,119 | $48,417 | — | $1,771,502 |\ | Accumulated deficit | $(1,241,908) | — | $(50,532)| $(1,292,440) |\ | Total stockholders' equity | $472,689 | $48,417 | $(50,532)| $478,198 | [Condensed Consolidated Statements of Cash Flows (unaudited)](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20(unaudited)) Condensed Consolidated Statements of Cash Flows (Unaudited) - Key Figures | Metric (in thousands) | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :-------------------- | :------------------------------ | :------------------------------ | | Net cash used in operating activities | **$(35,814)** | **$(48,774)** |\ | Net cash used in investing activities | **$(12,359)** | **$(1,786)** |\ | Net cash provided by financing activities | **$22,966** | **$3,263** |\ | Net decrease in cash, cash equivalents, and restricted cash | $(25,227) | $(47,244) |\ | Cash, cash equivalents, and restricted cash at end of period | $203,905 | $242,037 | - Non-cash investing activities for the nine months ended June 30, 2025, included **$53.9 million** in equity securities and **$1.7 million** in promissory notes received as consideration for the sale of a business[28](index=28&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=14&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides comprehensive notes to the unaudited condensed consolidated financial statements [Note 1. Organization and Description of Business](index=14&type=section&id=1.%20Organization%20and%20Description%20of%20Business) This note describes Twist Bioscience's synthetic biology business and the sale of its DNA Data Storage unit - Twist Bioscience is a synthetic biology company with a disruptive DNA synthesis platform for manufacturing synthetic DNA, RNA, and antibody proteins[33](index=33&type=chunk)[34](index=34&type=chunk) - On May 2, 2025, the company sold its DNA Data Storage business to Atlas Data Storage, Inc[35](index=35&type=chunk) Net Income (Loss) and Accumulated Deficit | Metric (in millions) | June 30, 2025 (3 months) | June 30, 2024 (3 months) | June 30, 2025 (9 months) | June 30, 2024 (9 months) | June 30, 2025 (Accumulated) | | :------------------- | :----------------------- | :----------------------- | :----------------------- | :----------------------- | :-------------------------- | | Net Income (Loss) | **$20.4** | **$(85.6)** | **$(50.5)** | **$(174.1)** | **$(1,292.4)** | [Note 2. Summary of Significant Accounting Policies](index=14&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the significant accounting policies used in preparing the financial statements - The unaudited condensed consolidated financial statements are prepared in accordance with GAAP, with certain information condensed or omitted compared to annual reports[38](index=38&type=chunk) - The company accounts for proceeds from the monetization of future milestone and royalty payments as a debt instrument, amortized using the effective interest rate method[44](index=44&type=chunk) - Investments in equity securities without readily determinable fair values are accounted for using the measurement alternative of cost less impairment, adjusted for observable price changes[46](index=46&type=chunk)[47](index=47&type=chunk) - The company elected to account for contingent consideration receivable from the Atlas Contribution Agreement as a gain contingency, recognizing it in earnings only after the contingency is resolved[48](index=48&type=chunk) [Note 3. Revenue](index=16&type=section&id=3.%20Revenue) This note details the company's revenue recognition policies and disaggregation by product, region, and industry - Revenue is generated from synthetic biology tools (synthetic genes, oligo pools, NGS tools, DNA libraries) and biopharma services for antibody discovery[53](index=53&type=chunk) Contract Balances (in thousands) | Metric | June 30, 2025 | September 30, 2024 | | :-------------- | :------------ | :----------------- | | Contract assets | $1,036 | $2,031 |\ | Contract liabilities | $6,234 | $2,131 | Revenues by Geographic Region (in thousands) | Region | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :------- | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Americas | $59,387 | $51,389 | $168,285 | $141,221 |\ | EMEA | $30,742 | $23,581 | $89,688 | $67,064 |\ | APAC | $5,928 | $6,494 | $19,590 | $19,979 |\ | Total | $96,057 | $81,464 | $277,563 | $228,264 | Revenues by Product (in thousands) | Product | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :---------------- | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Synthetic genes | $27,680 | $24,948 | $82,387 | $67,031 |\ | Oligo pools | $5,423 | $4,166 | $15,228 | $12,295 |\ | DNA libraries | $2,056 | $3,848 | $7,867 | $10,318 |\ | Antibody discovery| $5,614 | $5,102 | $17,009 | $15,029 |\ | NGS tools | $55,284 | $43,400 | $155,072 | $123,591 |\ | Total | $96,057 | $81,464 | $277,563 | $228,264 | Revenues by Industry (in thousands) | Industry | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :------------------------ | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Industrial chemicals/materials | $23,103 | $23,188 | $67,101 | $59,730 |\ | Academic research | $15,931 | $14,892 | $50,004 | $42,387 |\ | Healthcare | $56,375 | $42,823 | $158,510 | $124,637 |\ | Food/agricultural | $648 | $561 | $1,948 | $1,510 |\ | Total | $96,057 | $81,464 | $277,563 | $228,264 | [Note 4. Cash, Cash Equivalents and Investments](index=18&type=section&id=4.%20Cash,%20Cash%20Equivalents%20and%20Investments) This note provides a breakdown of the company's cash, cash equivalents, and investment balances Cash, Cash Equivalents and Investments (in thousands) | Metric | June 30, 2025 | September 30, 2024 | | :-------------------------------------- | :------------ | :----------------- | | Cash and cash equivalents | $201,373 | $226,316 |\ | Short-term investments | $49,425 | $50,083 |\ | Investment in equity securities of privately held companies | $54,337 | $1,525 |\ | Total cash, cash equivalents and investments | $305,135 | $277,924 | [Note 5. Fair Value Measurement](index=19&type=section&id=5.%20Fair%20Value%20Measurement) This note describes the company's fair value measurement hierarchy for financial assets - Fair value measurements are based on ASC 820, utilizing a three-level hierarchy (Level 1: quoted prices in active markets; Level 2: observable inputs other than Level 1 prices; Level 3: unobservable inputs)[67](index=67&type=chunk)[68](index=68&type=chunk) Assets Measured at Fair Value on a Recurring Basis (in thousands) | Asset | June 30, 2025 (Fair Value) | September 30, 2024 (Fair Value) | | :------------------------ | :------------------------- | :------------------------------ | | Money market funds | $167,973 | $199,858 |\ | U.S. government treasury bills | $49,425 | $50,083 |\ | Total financial assets | $217,398 | $249,941 | - All financial assets measured at fair value (money market funds and U.S. government treasury bills) are classified as Level 1, indicating quoted prices in active markets[70](index=70&type=chunk)[71](index=71&type=chunk) [Note 6. Investment in Equity Securities](index=20&type=section&id=6.%20Investment%20in%20Equity%20Securities) This note details the company's investment in equity securities, including the sale of its DNA Data Storage business - The company sold its DNA digital data storage business to Atlas Data Storage, Inc. on May 2, 2025[74](index=74&type=chunk) Consideration and Gain on Sale of Business (in thousands) | Item | As of May 2, 2025 | | :------------------------ | :---------------- | | Fair value of Series Seed-1 Preferred Stock | $53,890 |\ | Fair value of promissory note receivable | $1,696 |\ | Upfront cash consideration | $2,500 |\ | **Total Sale consideration** | **$58,086** |\ | Net assets sold | $(9,239) |\ | **Gain on sale of business** | **$48,847** | - The company's investment in Atlas is accounted for at fair value using the measurement alternative method, as Atlas is a private company without readily determinable fair value[75](index=75&type=chunk) - Atlas is a variable interest entity, but the company is not its primary beneficiary, with a maximum exposure to loss of **$57.4 million** from its investment, promissory note, and other receivables[79](index=79&type=chunk) [Note 7. Balance Sheet Components](index=23&type=section&id=7.%20Balance%20Sheet%20Components) This note provides detailed breakdowns of various balance sheet components, including inventories and property Allowance for Credit Losses (in thousands) | Metric | June 30, 2025 | September 30, 2024 | | :-------------------------- | :------------ | :----------------- | | Allowance for credit losses | **$0.5** | $0.7 | Inventories (in thousands) | Component | June 30, 2025 | September 30, 2024 | | :-------------- | :------------ | :----------------- | | Raw materials | $17,497 | $17,316 |\ | Work-in-process | $1,960 | $2,146 |\ | Finished goods | $6,481 | $4,616 |\ | Total | $25,938 | $24,078 | Property and Equipment, net (in thousands) | Component | June 30, 2025 | September 30, 2024 | | :------------------------ | :------------ | :----------------- | | Gross carrying amount | $184,633 | $178,163 |\ | Accumulated depreciation and amortization | $(89,282) | $(75,643) |\ | Net book value | $95,351 | $102,520 | Other Current Liabilities (in thousands) | Component | June 30, 2025 | September 30, 2024 | | :------------------------ | :------------ | :----------------- | | Income and other taxes payable | $4,253 | $2,725 |\ | Contract liabilities | $6,324 | $2,131 |\ | Other current liabilities | $500 | $961 |\ | Total | $11,077 | $5,817 | [Note 8. Goodwill and Intangible Assets](index=23&type=section&id=8.%20Goodwill%20and%20Intangible%20Assets) This note details the company's goodwill and finite-lived intangible assets, including changes from business sale Goodwill Balance (in thousands) | Metric | June 30, 2025 | September 30, 2024 | | :-------------------------- | :------------ | :----------------- | | Balance at beginning of period/year | $85,811 | $85,811 |\ | Sale of business | $(3,616) | $— |\ | Balance at end of period/year | $82,195 | $85,811 | Finite-Lived Intangible Assets (in thousands) | Component | June 30, 2025 (Net Book Value) | September 30, 2024 (Net Book Value) | | :------------------ | :----------------------------- | :---------------------------------- | | Developed Technology | $13,688 | $14,478 |\ | Customer Relationships | $— | $— |\ | Tradenames & Trademarks | $— | $— |\ | Total | $13,688 | $14,478 | Total Amortization Expense Related to Intangible Assets (in thousands) | Period | 2025 | 2024 | | :------------------------ | :-------- | :-------- | | Three months ended June 30 | **$0.3** | $1.3 |\ | Nine months ended June 30 | **$0.8** | $3.9 | [Note 9. Leases](index=25&type=section&id=9.%20Leases) This note outlines the company's operating lease commitments and related expenses - The company leases facilities under non-cancellable operating leases expiring through 2044[90](index=90&type=chunk) Future Minimum Lease Payments (in thousands) as of June 30, 2025 | Years ending September 30 | Operating leases | | :------------------------ | :--------------- | | Remainder of 2025 | $3,858 |\ | 2026 | $13,963 |\ | 2027 | $8,450 |\ | 2028 | $8,510 |\ | 2029 | $6,609 |\ | Thereafter | $81,405 |\ | Total minimum lease payments | $122,795 |\ | Less: imputed interest | $(44,645) |\ | Total operating lease liabilities | $78,150 | Lease Expense and Income (in thousands) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :---------------------- | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Operating lease costs | $3,823 | $3,800 | $11,306 | $11,800 |\ | Sublease income | **$(417)** | $— | **$(417)** | $— | [Note 10. Commitments and Contingencies](index=26&type=section&id=10.%20Commitments%20and%20Contingencies) This note describes the company's legal commitments and contingencies, including ongoing lawsuits - The company is a defendant in a securities class action lawsuit (Peters v. Twist Bioscience Corporation, et al.) filed in December 2022, alleging violations of federal securities laws based on a Scorpion Capital report[95](index=95&type=chunk)[97](index=97&type=chunk) - A shareholder derivative suit (Shumacher vs. Leproust et al.) was filed in September 2023, based on similar allegations as the securities class action, and is currently stayed[99](index=99&type=chunk) - The company intends to vigorously defend itself against these claims, and the securities class action is awaiting a judge's decision on a motion to dismiss[98](index=98&type=chunk) [Note 11. Related Party Transactions](index=28&type=section&id=11.%20Related%20Party%20Transactions) This note details transactions with related parties, including Atlas Data Storage, Inc Revenues from Related Parties (in thousands) | Period | 2025 | 2024 | | :------------------------ | :-------- | :-------- | | Three months ended June 30 | $2,800 | $4,100 |\ | Nine months ended June 30 | $9,600 | $9,700 | - Atlas Data Storage, Inc. became a related party after the company's investment, leading to sublease income of **$0.4 million** for both the three and nine months ended June 30, 2025[102](index=102&type=chunk) - As of June 30, 2025, the company held a promissory note receivable from Atlas of **$1.7 million** and other receivables of **$1.7 million** related to transition services and sublease income[103](index=103&type=chunk) [Note 12. Income Taxes](index=30&type=section&id=12.%20Income%20Taxes) This note provides information on the company's income tax provisions and the impact of tax reforms Income Tax Provisions (in thousands) | Period | 2025 | 2024 | | :------------------------ | :-------- | :-------- | | Three months ended June 30 | **$0.2** | $0.2 |\ | Nine months ended June 30 | **$0.5** | $0.7 | - The sale of the DNA digital data storage business did not impact the income tax provision due to carryover tax attributes (net operating losses) and a valuation allowance[107](index=107&type=chunk) - Recently enacted U.S. tax reform legislation (H.R.1) is not expected to have a material impact on the company's financial statements[108](index=108&type=chunk) [Note 13. Common Stock](index=30&type=section&id=13.%20Common%20Stock) This note details changes in the company's common stock authorization and outstanding shares - The authorized common stock was increased to **200.0 million shares** at a par value of **$0.00001 per share** in February 2025[110](index=110&type=chunk) [Note 14. Stock-based Compensation](index=30&type=section&id=14.%20Stock-based%20Compensation) This note outlines the company's stock-based compensation plans and related expenses Total Stock-based Compensation Expense (in thousands) | Period | 2025 | 2024 | | :------------------------ | :-------- | :-------- | | Three months ended June 30 | $16,057 | $13,734 |\ | Nine months ended June 30 | $48,376 | $38,578 | - As of June 30, 2025, there was **$72.6 million** of unrecognized compensation cost for restricted stock units, expected to be recognized over **2.8 years**[115](index=115&type=chunk) - Unrecognized compensation costs for performance-based restricted stock units totaled **$45.2 million** (based on maximum achievement), expected to be recognized over **1.7 years**[117](index=117&type=chunk) - Stock options outstanding at June 30, 2025, were **1,463 thousand shares** with a weighted average exercise price of **$30.77**[119](index=119&type=chunk) [Note 15. Net Income (Loss) Per Share](index=33&type=section&id=15.%20Net%20Income%20(Loss)%20Per%20Share) This note presents the calculation of basic and diluted net income (loss) per share Net Income (Loss) Per Share | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :------------------------ | :------------------------------- | :------------------------------- | :------------------------------ | :------------------------------ | | Net income (loss) | $20,390 | $(85,571) | $(50,532) | $(174,071) |\ | Basic EPS | $0.34 | $(1.47) | $(0.85) | $(3.01) |\ | Diluted EPS | $0.33 | $(1.47) | $(0.85) | $(3.01) | - Potentially dilutive common shares, totaling **3,719 thousand** for the three months and **5,553 thousand** for the nine months ended June 30, 2025, were excluded from diluted EPS calculations when their effect was antidilutive[122](index=122&type=chunk) [Note 16. Liability Related to the Sales of Future Revenue](index=35&type=section&id=16.%20Liability%20Related%20to%20the%20Sales%20of%20Future%20Revenue) This note describes the liability related to the sale of future milestone and royalty payments - On October 21, 2024, the company received a **$15.0 million** upfront payment from XOMA (US) LLC for the right to receive half of future milestone and royalty payments from certain antibody discovery and biopharma services agreements[123](index=123&type=chunk) - This payment was recorded as a liability related to the sale of future revenue, to be amortized using the effective interest method[123](index=123&type=chunk) - No imputed interest expense was recorded for the nine months ended June 30, 2025, as the estimated aggregate future milestone and royalty payments did not exceed **$15.0 million**[125](index=125&type=chunk) [Note 17. Impairment of long-lived assets](index=37&type=section&id=17.%20Impairment%20of%20long-lived%20assets) This note details the impairment loss recognized for the Biopharma asset group - An impairment indicator was identified for the Biopharma asset group on June 30, 2024, due to lower than forecasted revenues[126](index=126&type=chunk) - An impairment loss of **$44.9 million** was recorded for the three and nine months ended June 30, 2024, allocated to property and equipment (**$9.1 million**) and finite-lived intangible assets (**$35.9 million**)[130](index=130&type=chunk) - The fair value of the Biopharma asset group was estimated using a discounted cash flow method with a **14% discount rate**, and fair values of individual assets were determined using income and market approaches[127](index=127&type=chunk)[128](index=128&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=38&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition, operations, liquidity, and capital resources, including the impact of the DNA Data Storage business sale [Overview](index=38&type=section&id=Overview) This overview describes Twist Bioscience's synthetic biology platform, recent business sale, and financial highlights - Twist Bioscience is a leading synthetic biology company with a disruptive DNA synthesis platform, expanding beyond DNA to synthetic RNA and antibody proteins[132](index=132&type=chunk) - The company sold its DNA Data Storage business to Atlas Data Storage, Inc. to accelerate technology development and allow strategic focus, retaining a minority ownership and potential future milestone/royalty payments[136](index=136&type=chunk) - The company reported net income of **$20.4 million** for the three months ended June 30, 2025, primarily due to the sale of the DNA Data Storage business, compared to a net loss of **$85.6 million** in the prior year[135](index=135&type=chunk) - As of June 30, 2025, the company had an accumulated net deficit of **$1,292.4 million** and **$250.8 million** in cash, cash equivalents, and short-term investments[135](index=135&type=chunk) [Results of Operations](index=39&type=section&id=Results%20of%20Operations) This section analyzes the company's financial performance for the three and nine months ended June 30, 2025 and 2024 [Comparison of the Three Months Ended June 30, 2025 and 2024](index=39&type=section&id=Comparison%20of%20the%20Three%20Months%20Ended%20June%2030,%202025%20and%202024) This section compares the company's financial results for the three months ended June 30, 2025 and 2024 - Revenues increased **18%** to **$96.1 million**, primarily due to growth in NGS tools and synthetic genes[140](index=140&type=chunk) - Gross margin increased to **53.4%** from **43.3%**, driven by increased revenues and stable manufacturing costs[140](index=140&type=chunk) - Loss from operations decreased to **$30.1 million** from **$88.9 million**, benefiting from the absence of a **$44.9 million** impairment charge in the prior year[140](index=140&type=chunk) - A gain of **$48.8 million** was recognized from the sale of the DNA digital data storage business[140](index=140&type=chunk) [Revenues](index=39&type=section&id=Revenues%20(Three%20Months)) This section analyzes revenue performance, highlighting growth drivers and key product contributions Revenues (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Revenues | $96,057 | $81,464 | $14,593 | 18% | - The increase in revenues was primarily due to growth in NGS tools revenue (**$11.9 million**) and synthetic genes revenue (**$2.7 million**), driven by healthcare and academic research industries[144](index=144&type=chunk) - The number of genes shipped increased by **12%** to approximately **237,000 genes** in Q3 2025 from **212,000** in Q3 2024[144](index=144&type=chunk) [Cost of Revenues](index=40&type=section&id=Cost%20of%20Revenues%20(Three%20Months)) This section analyzes cost of revenues and gross margin, detailing factors influencing changes Cost of Revenues and Gross Margin (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Cost of revenues | $44,760 | $46,193 | $(1,433) | (3)% |\ | Gross profit | $51,297 | $35,271 | $16,026 | 45% |\ | Gross margin | **53.4%** | **43.3%** | **10.1% pts** | | - The decrease in cost of revenues was mainly due to a **$1.7 million** decrease in depreciation and amortization, **$0.5 million** decrease in production overheads, and **$0.3 million** decrease in material costs[147](index=147&type=chunk) [Research and Development Expenses](index=42&type=section&id=Research%20and%20Development%20Expenses%20(Three%20Months)) This section analyzes research and development expenses, noting changes in personnel and stock-based compensation Research and Development Expenses (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | R&D expenses | $18,047 | $22,469 | $(4,422) | (20)% | - The decrease was primarily driven by a **$2.4 million** reduction in personnel costs and a **$1.5 million** reduction in stock-based compensation expenses, mainly due to the transition of DNA digital data storage employees[148](index=148&type=chunk) [Selling, General and Administrative Expenses](index=42&type=section&id=Selling,%20General%20and%20Administrative%20Expenses%20(Three%20Months)) This section analyzes selling, general and administrative expenses, detailing increases in compensation and marketing Selling, General and Administrative Expenses (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | SG&A expenses | $63,370 | $56,794 | $6,576 | 12% | - The increase was primarily due to a **$2.8 million** increase in stock-based compensation, **$1.9 million** in personnel costs, **$1.3 million** in marketing costs, and **$1.0 million** in IT services costs[149](index=149&type=chunk) [Impairment of long-lived assets](index=42&type=section&id=Impairment%20of%20long-lived%20assets%20(Three%20Months)) This section details the impairment of long-lived assets for the three months ended June 30, 2024 Impairment of Long-Lived Assets (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :--- | :--- | :----- | :------- | | Impairment | $— | **$44,930** | $(44,930) | (100)% | [Gain on Sale of business](index=42&type=section&id=Gain%20on%20Sale%20of%20business%20(Three%20Months)) This section details the gain recognized from the sale of the DNA digital data storage business Gain on Sale of Business (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :--- | :-------- | :------- | | Gain on sale | **$48,847** | $— | **$48,847** | N/A | [Interest and Other Income (Expense), net](index=44&type=section&id=Interest%20and%20Other%20Income%20(Expense),%20net%20(Three%20Months)) This section analyzes interest and other income (expense), net, for the period Interest and Other Income (Expense), net (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Interest income | **$2,690** | **$3,663** | **$(973)** | (27)% |\ | Other income (expense), net | **$(836)** | **$(121)** | **$(715)** | 591% |\ | Total | **$1,854** | **$3,542** | **$(1,688)** | (48)% | [Income Tax Expense](index=44&type=section&id=Income%20Tax%20Expense%20(Three%20Months)) This section details the company's income tax expense for the period Income Tax Expense (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :--- | :--- | :----- | :------- | | Income tax expense | **$(191)** | **$(191)** | $— | 0% | [Comparison of the Nine Months Ended June 30, 2025 and 2024](index=44&type=section&id=Comparison%20of%20the%20Nine%20Months%20Ended%20June%2030,%202025%20and%202024) This section compares the company's financial results for the nine months ended June 30, 2025 and 2024 - Revenues increased **22%** to **$277.6 million**, primarily due to growth in NGS tools and synthetic genes[155](index=155&type=chunk) - Gross margin increased to **50.5%** from **41.7%**, driven by increased revenues and stable manufacturing costs[162](index=162&type=chunk) - The company recognized a **$48.8 million** gain on the sale of its DNA digital data storage business[167](index=167&type=chunk) - Research and development expenses decreased by **9%**, while selling, general and administrative expenses increased by **11%**[164](index=164&type=chunk)[165](index=165&type=chunk) [Revenues](index=44&type=section&id=Revenues%20(Nine%20Months)) This section analyzes revenue performance, highlighting growth drivers and key product contributions Revenues (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Revenues | $277,563 | $228,264 | $49,299 | 22% | - The increase was primarily due to growth in NGS tools revenue (**$31.5 million**) and synthetic genes revenue (**$15.4 million**)[161](index=161&type=chunk) - The number of genes shipped increased by **16%** to approximately **669,000 genes** in the nine months ended June 30, 2025, from **576,000** in the prior year[161](index=161&type=chunk) [Cost of Revenues](index=46&type=section&id=Cost%20of%20Revenues%20(Nine%20Months)) This section analyzes cost of revenues and gross margin, detailing factors influencing changes Cost of Revenues and Gross Margin (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Cost of revenues | $137,398 | $133,148 | $4,250 | 3% |\ | Gross profit | $140,165 | $95,116 | $45,049 | 47% |\ | Gross margin | **50.5%** | **41.7%** | **8.8% pts** | | - The increase in cost of revenues was primarily due to a **$7.3 million** increase in material costs and a **$2.3 million** increase in stock-based compensation, partially offset by a **$4.4 million** decrease in depreciation and amortization[162](index=162&type=chunk) [Research and Development Expenses](index=46&type=section&id=Research%20and%20Development%20Expenses%20(Nine%20Months)) This section analyzes research and development expenses, noting changes in personnel and stock-based compensation Research and Development Expenses (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | R&D expenses | $63,271 | $69,718 | $(6,447) | (9)% | - The decrease was primarily due to a **$3.3 million** reduction in personnel costs, **$1.4 million** in stock-based compensation, and **$1.5 million** in depreciation expense, linked to the DNA digital data storage business sale[164](index=164&type=chunk) [Selling, General and Administrative Expenses](index=47&type=section&id=Selling,%20General%20and%20Administrative%20Expenses%20(Nine%20Months)) This section analyzes selling, general and administrative expenses, detailing increases in compensation and marketing Selling, General and Administrative Expenses (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | SG&A expenses | $183,219 | $165,256 | $17,963 | 11% | - The increase was primarily due to an **$8.9 million** increase in stock-based compensation, **$3.8 million** in personnel costs, **$1.2 million** in marketing costs, and **$2.5 million** in other third-party spending[165](index=165&type=chunk) [Impairment of long-lived assets](index=47&type=section&id=Impairment%20of%20long-lived%20assets%20(Nine%20Months)) This section details the impairment of long-lived assets for the nine months ended June 30, 2024 Impairment of Long-Lived Assets (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :--- | :--- | :----- | :------- | | Impairment | $— | **$44,930** | $(44,930) | (100)% | [Gain on Sale of business](index=47&type=section&id=Gain%20on%20Sale%20of%20business%20(Nine%20Months)) This section details the gain recognized from the sale of the DNA digital data storage business Gain on Sale of Business (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :--- | :-------- | :------- | | Gain on sale | **$48,847** | $— | **$48,847** | N/A | [Interest and Other Income (Expense), net](index=47&type=section&id=Interest%20and%20Other%20Income%20(Expense),%20net%20(Nine%20Months)) This section analyzes interest and other income (expense), net, for the period Interest and Other Income (Expense), net (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :-------- | :-------- | :-------- | :------- | | Interest income | **$8,731** | **$11,724** | **$(2,993)** | (26)% |\ | Other expense | **$(1,323)** | **$(351)** | **$(972)** | 277% |\ | Total | **$7,408** | **$11,373** | **$(3,965)** | (35)% | [Income Tax Expense](index=49&type=section&id=Income%20Tax%20Expense%20(Nine%20Months)) This section details the company's income tax expense for the period Income Tax Expense (Nine Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | Change | % Change | | :-------------------- | :--- | :--- | :----- | :------- | | Income tax expense | **$(462)** | **$(656)** | **$194** | **(30)%** | [Liquidity and Capital Resources](index=49&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's liquidity, capital resources, and cash flow activities [Sources of Liquidity](index=49&type=section&id=Sources%20of%20Liquidity) This section outlines the company's primary sources of liquidity and recent financing activities - The company's operations are financed through public equity, private placements, credit facilities, and revenue[171](index=171&type=chunk) Cash and Investments (in millions) | Metric | June 30, 2025 | | :------------------------ | :------------ | | Cash and cash equivalents | **$201.4** |\ | Short-term investments | **$49.4** | - Recent liquidity sources include a **$15.0 million** upfront payment from XOMA for future revenue rights and **$2.5 million** cash from the sale of the DNA digital data storage business to Atlas[172](index=172&type=chunk)[173](index=173&type=chunk) [Operating Capital Requirements](index=49&type=section&id=Operating%20Capital%20Requirements) This section details the company's operating capital requirements and capital expenditure commitments - Primary capital uses are compensation, manufacturing, laboratory supplies, legal, regulatory, general overhead, and capital expenditures[174](index=174&type=chunk) - As of June 30, 2025, the company had **$10.3 million** in commitments for capital expenditures[174](index=174&type=chunk) [Cash Flows](index=49&type=section&id=Cash%20Flows) This section summarizes the company's cash flows from operating, investing, and financing activities Summary of Cash Flows (in thousands) | Activity | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :---------------------------- | :------------------------------ | :------------------------------ | | Net cash used in operating activities | **$(35,814)** | **$(48,774)** |\ | Net cash provided by (used in) investing activities | **$(12,359)** | **$(1,786)** |\ | Net cash provided by financing activities | **$22,966** | **$3,263** | [Operating Activities](index=49&type=section&id=Operating%20Activities) This section analyzes net cash used in operating activities, highlighting changes in net loss and non-cash items Net Cash Used in Operating Activities (in thousands) | Metric | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :-------------------------------------- | :------------------------------ | :------------------------------ | | Net cash used in operating activities | **$(35,814)** | **$(48,774)** | - The decrease in cash used was driven by a lower net loss (**$50.5 million** vs. **$174.1 million**), adjusted for non-cash items including **$48.4 million** in stock-based compensation and a **$48.8 million** gain on sale of business in 2025[176](index=176&type=chunk)[177](index=177&type=chunk) - Changes in operating assets and liabilities resulted in a net cash outflow of **$5.6 million** in 2025, mainly due to increases in accounts receivable, inventories, and prepaid expenses, partially offset by increases in accounts payable, other liabilities, and accrued expenses[177](index=177&type=chunk) [Investing Activities](index=51&type=section&id=Investing%20Activities) This section analyzes net cash used in investing activities, including property purchases and business sale proceeds Net Cash Used in Investing Activities (in thousands) | Metric | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :-------------------------------------- | :------------------------------ | :------------------------------ | | Net cash used in investing activities | **$(12,359)** | **$(1,786)** | - Investing activities included **$15.6 million** in property and equipment purchases and **$2.5 million** in proceeds from the sale of the data storage business in 2025[179](index=179&type=chunk) [Financing Activities](index=51&type=section&id=Financing%20Activities) This section analyzes net cash provided by financing activities, including future revenue sales and stock exercises Net Cash Provided by Financing Activities (in thousands) | Metric | Nine Months Ended June 30, 2025 | Nine Months Ended June 30, 2024 | | :-------------------------------------- | :------------------------------ | :------------------------------ | | Net cash provided by financing activities | **$22,966** | **$3,263** | - Financing activities in 2025 included **$15.0 million** from XOMA for the sale of future revenue, **$5.6 million** from stock option exercises, and **$2.4 million** from the employee stock purchase plan[181](index=181&type=chunk) [Off-Balance Sheet Arrangements](index=51&type=section&id=Off-Balance%20Sheet%20Arrangements) This section confirms the absence of off-balance sheet arrangements - The company has no off-balance sheet arrangements[183](index=183&type=chunk) [Contractual Obligations and Other Commitments](index=51&type=section&id=Contractual%20Obligations%20and%20Other%20Commitments) This section notes that contractual obligations have not materially changed from the annual report - Contractual obligations have not materially changed from the Annual Report on Form 10-K[184](index=184&type=chunk) [Critical Accounting Policies and Significant Management Estimates](index=51&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Management%20Estimates) This section discusses critical accounting policies, including the gain on sale of business calculation - The calculation of gain on sale of business is a critical accounting policy, involving fair value measurement of the investment in Atlas Series Seed-1 Preferred Stock[186](index=186&type=chunk) - The fair value of the Atlas investment was determined using the backsolve method, based on a recent financing round, and an option pricing allocation method (OPM) to allocate total equity value[186](index=186&type=chunk) [Recent Accounting Pronouncements](index=52&type=section&id=Recent%20Accounting%20Pronouncements) This section outlines recent accounting pronouncements and their expected impact on the company - Recent accounting pronouncements include ASU No. 2023-09 (Income Taxes), ASU No. 2023-07 (Segment Reporting), and ASU 2024-03 (Expense Disaggregation Disclosures)[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk) - The company does not expect these new standards to have a material impact on its financial position or results of operations upon adoption[49](index=49&type=chunk)[50](index=50&type=chunk)[51](index=51&type=chunk)[52](index=52&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=52&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure remains materially unchanged since September 30, 2024 - The company's exposure to market risk has not materially changed since September 30, 2024[189](index=189&type=chunk) [Item 4. Controls and Procedures](index=52&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective, with no material changes in internal control - The company's disclosure controls and procedures were evaluated and deemed effective as of June 30, 2025[190](index=190&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter ended June 30, 2025[191](index=191&type=chunk) [Part II. Other Information](index=54&type=section&id=PART%20II.%20OTHER%20INFORMATION) This part provides other information, including legal proceedings, risk factors, and executive trading plans [Item 1. Legal Proceedings](index=54&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in legal proceedings, detailed in Note 10, with management expecting no material adverse effect - The company is involved in material pending legal proceedings, as described in Note 10 of the financial statements[193](index=193&type=chunk) - Management believes the final disposition of these legal matters will not materially adversely affect the company's business, financial position, results of operations, or cash flows[193](index=193&type=chunk) [Item 1A. Risk Factors](index=54&type=section&id=Item%201A.%20Risk%20Factors) This section references risk factors from previous reports, noting no material changes since the last annual report - Readers should consider risk factors detailed in the Annual Report on Form 10-K and previous Quarterly Report on Form 10-Q[194](index=194&type=chunk) - There have been no material changes in the company's risk factors from those described in its Annual Report on Form 10-K[194](index=194&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=54&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities - There were no unregistered sales of equity securities[195](index=195&type=chunk) [Item 3. Defaults Upon Senior Securities](index=54&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - There were no defaults upon senior securities[196](index=196&type=chunk) [Item 4. Mine Safety Disclosures](index=54&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable[197](index=197&type=chunk) [Item 5. Other Information](index=54&type=section&id=Item%205.%20Other%20Information) Key executives adopted Rule 10b5-1 trading plans in May 2025 for potential common stock sales - Several key executives, including the Chief Legal Officer, CFO, President & COO, and CEO, adopted Rule 10b5-1 trading plans in May 2025[198](index=198&type=chunk)[199](index=199&type=chunk)[200](index=200&type=chunk)[201](index=201&type=chunk) Rule 10b5-1 Trading Plans Adopted in May 2025 | Executive | Shares for Potential Sale | Expiration Date (Earlier of) | | :------------------------ | :------------------------ | :--------------------------- | | Dennis Cho (Chief Legal Officer) | **31,945** | **May 15, 2026** |\ | Adam Laponis (Chief Financial Officer) | **24,000** | **August 20, 2026** |\ | Patrick Finn (President & COO) | **97,496** | **May 13, 2026** |\ | Emily M. Leproust (CEO) | **458,276** | **September 16, 2026** | [Item 6. Exhibits](index=57&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including agreements for the DNA Data Storage business sale and certifications - Exhibits include the Contribution Agreement, License Agreement, and MES Software License Agreement related to the sale of the DNA Data Storage business to Atlas Data Storage, Inc[204](index=204&type=chunk) - Certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 by the Chief Executive Officer and Chief Financial Officer are also filed[204](index=204&type=chunk) - The financial statements are provided in iXBRL (inline eXtensible Business Reporting Language) format[204](index=204&type=chunk) [Signatures](index=59&type=section&id=SIGNATURES) The report is signed by the Chief Financial Officer on behalf of Twist Bioscience Corporation - The report is signed by Adam Laponis, Chief Financial Officer, on behalf of Twist Bioscience Corporation, dated August 4, 2025[207](index=207&type=chunk)

Financial Data and Key Metrics Changes - For the fiscal year 2025 third quarter, the company reported record revenue of $96.1 million, an increase of 18% year over year [9][20] - Gross margin for the quarter was 53.4%, up from 43.3% in the previous year, reflecting improved operational efficiency and cost management [10][24] - Adjusted EBITDA loss was approximately $8 million, an improvement of about $14 million compared to the previous year [26] Business Line Data and Key Metrics Changes - Revenue from the synthetic biology (SynBio) segment was $35.2 million, reflecting a 7% year-over-year growth [10][20] - Next-generation sequencing (NGS) revenue increased to $55.3 million, a 27% year-over-year growth, driven by commercial assays for diagnostic tests [11][20] - Biopharma services revenue was $5.6 million, a 10% increase year over year [12][20] Market Data and Key Metrics Changes - Healthcare revenue rose to $56.4 million, a 32% increase compared to the same period last year [21] - Industrial chemical revenue was approximately flat at $23.1 million, while academic revenue grew by 7% to $15.9 million [22] - Geographically, revenue in the Americas increased by 16% to $59.4 million, while EMEA revenue rose by 30% to $30.7 million [23] Company Strategy and Development Direction - The company is focused on expanding its product portfolio and increasing market reach, particularly in the academic sector [9][10] - There is an emphasis on leveraging AI for drug discovery and enhancing customer engagement to drive growth [34] - The company aims to achieve adjusted EBITDA breakeven as a key operational milestone, with plans for continued top-line growth [18][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the SynBio and NGS segments, citing strong customer relationships and demand [11][34] - The company is adapting to market shifts and challenges, viewing them as opportunities for innovation and growth [31][34] - Management highlighted the importance of maintaining gross margins above 50% while focusing on revenue growth [35] Other Important Information - The company ended the quarter with approximately $250.8 million in cash, cash equivalents, and short-term investments [27] - Guidance for total revenue for fiscal year 2025 is narrowed to $374 million to $376 million, indicating a year-over-year growth of approximately 19.7% at the midpoint [28] Q&A Session Summary Question: Insights on SynBio growth and customer trends - Management noted that existing products resonate well with customers, and there is a strong pipeline of new product introductions [39][40] Question: NGS product launch timelines and expectations - Management confirmed that product launches are on track, with expectations for significant growth in 2026 [46][49] Question: Impact of customer transition on revenue - Management indicated a $5 million revenue impact in Q4 due to a customer transition, with expectations for recovery in Q1 [60][61] Question: Academic market growth attribution - Management attributed growth in the U.S. academic market to the company's technology advantage and value proposition [64][66] Question: International growth and market adaptation - Management emphasized the company's low variable costs and ability to navigate tariff uncertainties, positioning it well for international growth [82]

Financial Data and Key Metrics Changes - The company reported record revenue of $96.1 million for the third quarter of fiscal 2025, an increase of 18% year over year [7][18] - Gross margin improved to 53.4%, up from 43.3% in the same quarter of fiscal 2024, reflecting better volume leverage and continuous improvement efforts [8][22] - Adjusted EBITDA loss was approximately $8 million, an improvement of about $14 million compared to fiscal 2024 [23] Business Line Data and Key Metrics Changes - Revenue from the synthetic biology (SynBio) segment was $35.2 million, reflecting a 7% year-over-year growth, with underlying revenue growth exceeding 20% when excluding a significant prior year order [9][18] - Next-generation sequencing (NGS) revenue reached $55.3 million, a 27% increase year over year, driven by commercial assays for diagnostic tests [9][19] - Biopharma services revenue was $5.6 million, growing 10% year over year, with a strong order funnel [10][19] Market Data and Key Metrics Changes - Healthcare revenue rose to $56.4 million, a 32% increase year over year, driven by large pharma and biotech customers [19] - Industrial chemical revenue was approximately flat at $23.1 million, while academic revenue grew 7% to $15.9 million [20] - Geographically, revenue in the Americas increased 16% to $59.4 million, EMEA revenue rose 30% to $30.7 million, and APAC revenue was $5.9 million [21] Company Strategy and Development Direction - The company is focused on expanding its product portfolio and increasing market reach, particularly in the academic sector [7][9] - Plans for new product launches in synthetic biology are expected to unlock new market opportunities [15][29] - The company aims to achieve adjusted EBITDA breakeven as a key operational milestone while continuing to drive top-line growth [16][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in synthetic biology and NGS, highlighting strong customer relationships and demand [9][31] - The company is adapting to market shifts and leveraging AI as a catalyst for increased demand across its product offerings [31][32] - Management acknowledged potential short-term fluctuations in certain product groups but emphasized the resilience of their diversified customer base [31][32] Other Important Information - The company ended the quarter with approximately $250.8 million in cash, cash equivalents, and short-term investments [24] - Guidance for total revenue in fiscal 2025 is narrowed to $374 million to $376 million, indicating a year-over-year growth of approximately 19.7% at the midpoint [24][25] Q&A Session Summary Question: Insights on SynBio growth and customer trends - Management noted that existing products resonate well with customers, and there is a significant opportunity to convert smaller accounts into future growth drivers [36][38] Question: NGS product launch timelines and expectations - Management confirmed that product launches have been on time, with expectations for significant growth in MRD revenue in 2026 [42][46] Question: Impact of customer transition on revenue - Management indicated a $5 million revenue impact in Q4 due to a customer transition, with expectations for some recovery in Q1 [50][60] Question: U.S. academic market growth drivers - Management attributed growth in the U.S. academic market to their technology advantage and the ability to provide more value for the same budget [62] Question: International growth and market adaptation - Management highlighted their low variable costs and ability to navigate tariff uncertainties, positioning them well for continued growth [78][80]

Financial Performance - The company reported revenue of $96.1 million, meeting guidance of approximately $94-97 million[9] - Adjusted EBITDA was $(8.0) million, exceeding guidance of $(13) million[9] - Gross margin reached 53.4%, achieving the target of exceeding 50%+ by 4QFY25[9] - Cash, cash equivalents, and short-term investments totaled $250.8 million as of June 30, 2025[34] Segment Revenue - SynBio revenue was $35.2 million, a 7% year-over-year growth, with approximately 237,000 genes shipped[13] - NGS revenue was $55.3 million, a 27% year-over-year growth, driven by expanded collaborations[16] - Biopharma Solutions revenue was $5.6 million, a 10% year-over-year growth, with $6.2 million in orders[19] FY2025 Guidance - Q4 FY2025 revenue is projected to be approximately $96 to $98 million, with SynBio contributing ~$38 to 39 million, NGS ~$52 to 53 million, and Biopharma ~$6 million[37] - Full-year FY2025 revenue is guided at approximately $374 to $376 million, with SynBio contributing ~$144 to 145 million, NGS ~$207 to 208 million, and Biopharma ~$23 million[37] - Full-year FY2025 Adjusted EBITDA is expected to be ~$(45 to 47M)[37]

[Third Quarter Fiscal 2025 Financial Performance](index=1&type=section&id=FISCAL%202025%20THIRD%20QUARTER%20FINANCIAL%20RESULTS) Twist Bioscience achieved record Q3 FY25 revenue of $96.1 million, an 18% increase, with a significant shift to $20.4 million net income due to a business sale gain Q3 FY2025 Key Financial Metrics (vs. Q3 FY2024) | Metric | Q3 FY2025 (Millions USD) | Q3 FY2024 (Millions USD) | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $96.1M | $81.5M | +18% | | Gross Margin | 53.4% | 43.3% | +10.1 p.p. | | Net Income (Loss) | $20.4M | ($85.6M) | N/A | | Adjusted EBITDA | ($8.0M) | ($22.0M) | +63.6% | Q3 FY2025 Revenue by Segment (vs. Q3 FY2024) | Segment | Q3 FY2025 Revenue (Millions USD) | Q3 FY2024 Revenue (Millions USD) | YoY Growth | | :--- | :--- | :--- | :--- | | NGS | $55.3M | $43.4M | +27% | | SynBio | $35.2M | $33.0M | +7% | | Biopharma | $5.6M | $5.1M | +10% | - The company's shift to net income was significantly impacted by a **$48.8 million gain** on the sale of a business during the quarter[19](index=19&type=chunk) - Operating expenses showed mixed changes, with **Research and Development expenses decreasing to $18.0 million** from $22.5 million, while **Selling, General and Administrative expenses increased to $63.4 million** from $56.8 million year-over-year[6](index=6&type=chunk) [Business and Operational Highlights](index=2&type=section&id=Recent%20Highlights%3A) The company expanded its customer base, increased gene shipments, and advanced strategic collaborations and product launches in Q3 - Operational metrics showed continued customer adoption with **2,484 customers** and **237,000 genes shipped**, up from the prior year[6](index=6&type=chunk) - Key strategic developments include a revised collaboration with Ginkgo Bioworks, an expanded collaboration with Element Biosciences, and the launch of a humanized transgenic mouse model for antibody discovery[6](index=6&type=chunk) [Updated Fiscal 2025 and Q4 Financial Guidance](index=2&type=section&id=Updated%20Fiscal%202025%20Financial%20Guidance) The company updated FY25 guidance, narrowing revenue to $374-$376 million and raising gross margin, while reaffirming its FY26 adjusted EBITDA breakeven goal Full Year Fiscal 2025 Guidance | Metric | FY2025 Guidance (Millions USD) | Previous Guidance (Millions USD) | | :--- | :--- | :--- | | Total Revenue | $374M - $376M | $372M - $379M | | Gross Margin | 50.5% - 51.0% | 49.5% | | Adjusted EBITDA | ($45.0M) - ($47.0M) | ($48.0M) - ($53.0M) | Fourth Quarter Fiscal 2025 Guidance | Metric | Q4 FY2025 Guidance (Millions USD) | | :--- | :--- | | Total Revenue | $96M - $98M | | Gross Margin | 51% - 52% | | Adjusted EBITDA | ($6.0M) - ($8.0M) | - The company maintains its long-term target of achieving **adjusted EBITDA breakeven by the end of fiscal 2026**[1](index=1&type=chunk)[7](index=7&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) This section presents unaudited financial statements, including detailed Q3 and YTD results, highlighting revenue growth, profitability, and liquidity [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Revenues for Q3 FY25 increased to $96.1 million, with a $48.8 million gain on business sale contributing to a net income of $20.4 million Q3 Income Statement Highlights (in thousands USD) | Line Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenues | $96,057 | $81,464 | | Loss from operations | ($30,120) | ($88,922) | | Gain on sale of business | $48,847 | $— | | Net income (loss) | $20,390 | ($85,571) | | Net income (loss) per share, basic | $0.34 | ($1.47) | [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were $643.6 million, with cash and equivalents at $250.8 million, reflecting a strong financial position Key Balance Sheet Items (in thousands USD) | Line Item | June 30, 2025 | September 30, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $201,373 | $226,316 | | Short-term investments | $49,425 | $50,083 | | Total current assets | $339,776 | $346,776 | | Total assets | $643,605 | $614,323 | | Total liabilities | $165,407 | $141,634 | | Total stockholders' equity | $478,198 | $472,689 | [Adjusted EBITDA Reconciliation](index=9&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA loss significantly improved to $8.0 million in Q3 FY25, reconciled from GAAP net income by adjusting for a business sale gain and non-cash expenses Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands USD) | Line Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | GAAP net income (loss) | $20,390 | ($85,571) | | Gain on sale of business | ($48,847) | $— | | Stock-based compensation expense | $16,057 | $13,734 | | Depreciation and amortization | $6,065 | $8,301 | | Impairment of long-lived assets | $— | $44,930 | | **Adjusted EBITDA** | **($7,998)** | **($21,957)** | [Supplementary Information](index=3&type=section&id=Supplementary%20Information) This section provides context for financial results, including non-GAAP measure definitions, investor call details, and forward-looking statement disclaimers - The company uses **non-GAAP measures such as Adjusted EBITDA**, which it believes enhances investors' ability to compare results period-over-period by excluding certain non-cash or non-recurring items[8](index=8&type=chunk) - A **reconciliation of forward-looking Adjusted EBITDA guidance to GAAP net loss is not provided** due to the difficulty in predicting certain reconciling items, such as stock-based compensation expense[11](index=11&type=chunk) - The report includes a safe harbor statement cautioning that **forward-looking statements**, including financial guidance, are subject to various risks and uncertainties that could cause actual results to differ materially[15](index=15&type=chunk)

Group 1 - The article highlights the ongoing discussions in the biotech sector, particularly focusing on covered call opportunities that have gained traction in recent quarters [1] - Twist Bioscience Corporation (NASDAQ: TWST) is being spotlighted for the first time in 2025, indicating a renewed interest in the company's performance and potential [2] - The investing group, The Biotech Forum, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2] Group 2 - The article does not provide any specific financial data or performance metrics for Twist Bioscience Corporation or other companies mentioned [3][4]

Summary of Twist Bioscience (TWST) FY Conference Call - June 03, 2025 Company Overview - **Company**: Twist Bioscience - **Industry**: Biotechnology, specifically in DNA synthesis and related applications Key Points and Arguments 1. **Revolutionary Technology**: Twist Bioscience has miniaturized DNA synthesis onto a silicon platform, enabling the writing of 1,000,000 oligonucleotides in one run, which is described as unprecedented in scale and quality [5][6] 2. **Growth Trajectory**: The company has shown consistent growth over approximately ten years, with a target of reaching $1 billion in revenue, supported by strong operational and commercial execution [7][8] 3. **Market Understanding**: The leadership team has deep knowledge of end markets, which allows for innovative product development and market share expansion [6][8] 4. **Production Capacity**: Twist has the capacity to produce 16,000,000 oligonucleotides per day, which supports a diverse product portfolio and strong differentiation in the market [7][49] 5. **Financial Performance**: For Q2 FY 2025, the company reported revenue of $92.8 million with a margin just under 50%, and an adjusted EBITDA of $14.8 million [50][51] 6. **Operational Efficiency**: The company maintains discipline in spending, with SG&A and R&D expenses controlled, allowing for margin expansion as revenue grows [10][31] 7. **Market Opportunities**: The company is positioned to capitalize on growing markets, including liquid biopsy and minimal residual disease (MRD), with innovative product offerings tailored to these segments [12][36] 8. **Customer-Centric Approach**: Twist focuses on providing a positive user experience, which is critical for customer retention and satisfaction [11][17] 9. **Sustainability**: The miniaturization of DNA synthesis significantly reduces the carbon footprint of gene production, enhancing the company's appeal in environmentally conscious markets [34][38] 10. **Diverse Product Portfolio**: The company offers a wide range of products across various segments, including Synbio, next-generation sequencing (NGS), and biopharma solutions, catering to diverse customer needs [32][47] Additional Important Insights 1. **Geopolitical Tailwinds**: The company benefits from being a U.S.-based manufacturer, which is advantageous in the current geopolitical climate [12] 2. **Long-Term Strategy**: Twist emphasizes a long-term approach to product development, focusing on sustained innovation rather than short-term gains [16][29] 3. **Competitive Landscape**: The company is aware of its competition and aims to differentiate itself through superior technology and customer service [22][40] 4. **Emerging Markets**: The company sees significant potential in the MRD market, which is characterized by bespoke tumor-informed panels that leverage Twist's strengths [58][60] 5. **Investment in Infrastructure**: Twist is investing heavily in automation and infrastructure to support its growth and capacity expansion, with a focus on maintaining low variable costs [28][31] This summary encapsulates the key points discussed during the conference call, highlighting Twist Bioscience's innovative technology, growth strategy, financial performance, and market opportunities.

Company Performance - Twist Bioscience (NASDAQ: TWST) reported solid results in the second quarter of FY2025, but the management team appeared downbeat on the earnings call [1] - The company has chosen to spin out its data storage segment, with a fairly modest value attached to the business [1] Investment Insights - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations due to poor understanding of long-term business prospects [1] - The firm believes excess risk-adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry [1] - Narweena's research process emphasizes company and industry fundamentals to uncover unique insights [1] Market Trends - An aging population with low population growth and stagnating productivity growth is expected to create a different opportunity set compared to past trends [1] - Many industries may face stagnation or secular decline, which could improve business performance if competition decreases [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale [1] - The economy is increasingly dominated by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is chasing a limited set of investment opportunities, driving up asset prices and compressing risk premia [1]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, and cash flows, for the period ended March 31, 2025 Condensed Consolidated Balance Sheet Highlights (unaudited) | (In thousands) | March 31, 2025 | September 30, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $210,437 | $226,316 | | Total current assets | $338,442 | $346,776 | | Total assets | $595,615 | $614,323 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $74,976 | $71,006 | | Total liabilities | $155,507 | $141,634 | | Total stockholders' equity | $440,108 | $472,689 | Condensed Consolidated Statements of Operations Highlights (unaudited) | (In thousands, except per share data) | Six Months Ended March 31, 2025 | Six Months Ended March 31, 2024 | | :--- | :--- | :--- | | Revenues | $181,506 | $146,800 | | Loss from operations | $(76,205) | $(95,866) | | Net loss | $(70,922) | $(88,500) | | Net loss per share, basic and diluted | $(1.19) | $(1.54) | Condensed Consolidated Statements of Cash Flows Highlights (unaudited) | (In thousands) | Six Months Ended March 31, 2025 | Six Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(34,414) | $(42,396) | | Net cash used in investing activities | $(2,962) | $(1,075) | | Net cash provided by financing activities | $21,140 | $355 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue disaggregation, financial instrument valuations, stock-based compensation, legal proceedings, and a significant subsequent spin-off event - As of March 31, 2025, the company had an accumulated deficit of **$1,312.8 million**, with management believing current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least one year[31](index=31&type=chunk) Revenue by Product (Six Months Ended March 31) | (in thousands) | 2025 | 2024 | | :--- | :--- | :--- | | Synthetic genes | $54,708 | $42,083 | | NGS tools | $99,788 | $80,191 | | Other | $26,910 | $24,526 | | **Total** | **$181,506** | **$146,800** | - On October 21, 2024, the company received an upfront payment of **$15.0 million** from XOMA Royalty for half of future potential milestone and royalty payments, recorded as a liability related to the sale of future revenue[98](index=98&type=chunk) - On May 2, 2025, the company sold its DNA digital data storage assets to Atlas Data Storage, Inc. for equity, cash, promissory notes, and potential future milestone and royalty payments[101](index=101&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial results, highlighting a **23% revenue increase** and improved gross margin for the three months ended March 31, 2025, alongside reduced net loss and improved operating cash flow, with sufficient capital for near-term operations [Overview](index=29&type=section&id=Overview) This overview describes the company's synthetic biology business and highlights key financial improvements for the three months ended March 31, 2025, including a **23% revenue increase** and improved gross margin Q2 FY2025 Financial Highlights (vs. Q2 FY2024) | Metric | Q2 FY2025 | Q2 FY2024 | | :--- | :--- | :--- | | Revenues | $92.8 million | $75.3 million | | Gross Margin | 49.6% | 41.0% | | Loss from Operations | $(41.6) million | $(48.9) million | | Net Loss | $(39.3) million | $(45.5) million | | Net Loss per Share | $(0.66) | $(0.79) | - The company serves approximately **3,562 customers** annually across healthcare, chemicals/materials, food/agriculture, and academic research industries[106](index=106&type=chunk) [Results of Operations](index=31&type=section&id=Results%20of%20Operations) This section details financial results for the three and six months ended March 31, 2025, showing **23% revenue growth**, significant gross margin expansion, and mixed trends in operating expenses Revenue Comparison (Three Months Ended March 31) | (in thousands) | 2025 | 2024 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Revenues | $92,793 | $75,302 | $17,491 | 23% | - For the three months ended March 31, 2025, the increase in revenues was primarily driven by a **$10.4 million** growth in NGS tools and a **$5.9 million** growth in synthetic genes[118](index=118&type=chunk) Operating Expenses Comparison (Three Months Ended March 31) | (in thousands) | 2025 | 2024 | % Change | | :--- | :--- | :--- | :--- | | Cost of Revenues | $46,765 | $44,420 | 5% | | Research & Development | $23,917 | $24,149 | (1)% | | Selling, General & Administrative | $63,671 | $55,622 | 14% | [Liquidity and Capital Resources](index=38&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company held **$210.4 million** in cash and equivalents, with operations financed through equity, debt, and revenue, and improved operating cash flow usage for the six-month period - As of March 31, 2025, the company held **$210.4 million** in cash and cash equivalents and **$46.7 million** in short-term investments[138](index=138&type=chunk) - Net cash used in operating activities decreased to **$34.4 million** for the six months ended March 31, 2025, compared to **$42.4 million** for the same period in 2024[143](index=143&type=chunk)[144](index=144&type=chunk) - Financing activities provided **$21.1 million** in cash, primarily from a **$15.0 million** upfront payment from XOMA for the sale of future revenue, alongside proceeds from stock option exercises and the ESPP[148](index=148&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=42&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's exposure to market risk has not materially changed since September 30, 2024, with further details available in the Annual Report on Form 10-K - The company's exposure to market risk has not materially changed since September 30, 2024[155](index=155&type=chunk) [Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - Based on an evaluation as of March 31, 2025, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[156](index=156&type=chunk) - No changes occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[157](index=157&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company is defending against a securities class action lawsuit and a related shareholder derivative suit, both stemming from a November 2022 short-seller report, with potential loss currently inestimable - The company is defending against a securities class action lawsuit (Peters v. Twist Bioscience Corporation, et al.) filed in December 2022, based on allegations from a Scorpion Capital report[75](index=75&type=chunk) - A shareholder derivative suit (Shumacher vs. Leproust et al.) was filed in September 2023 based on substantially the same allegations as the securities class action, currently stayed pending a motion to dismiss in the class action case[79](index=79&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) Key risk factors include adverse global economic conditions, geopolitical tensions, U.S. policy changes, and the potential failure to realize anticipated benefits from the DNA data storage business spin-out - Adverse global economic conditions, geopolitical tensions, and U.S. policy changes like new tariffs and halts on federal research grants could negatively affect the company's business and financial condition[163](index=163&type=chunk) - The company may not achieve the anticipated benefits from the May 2025 spin-out of its DNA data storage business to Atlas Data Storage, and the divestiture reduces business diversification[164](index=164&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[165](index=165&type=chunk) [Defaults Upon Senior Securities](index=44&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[166](index=166&type=chunk) [Mine Safety Disclosures](index=46&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[167](index=167&type=chunk) [Other Information](index=46&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted, modified, or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the fiscal quarter ended March 31, 2025 - No directors or officers adopted, modified, or terminated a Rule 10b5-1 trading arrangement during the quarter ended March 31, 2025[168](index=168&type=chunk) [Exhibits](index=47&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including amendments to the Certificate of Incorporation, the 2018 Equity Incentive Plan, and CEO/CFO certifications - Key exhibits filed include the Certificate of Amendment to Amended and Restated Certificate of Incorporation, the Amended and Restated 2018 Equity Incentive Plan, and certifications by the CEO and CFO[170](index=170&type=chunk)